uniQure (NASDAQ:QURE) Shares Gap Down – Time to Sell?

uniQure (NASDAQ:QURE) gapped down before the market opened on Tuesday . The stock had previously closed at $14.53, but opened at $14.07. uniQure shares last traded at $13.83, with a volume of 60,923 shares.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on QURE shares. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Tuesday, March 4th. The Goldman Sachs Group increased their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Finally, Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Price Performance

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50-day moving average is $13.83 and its two-hundred day moving average is $10.39. The company has a market capitalization of $759.24 million, a P/E ratio of -2.83 and a beta of 0.36.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 over the last ninety days. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Atria Investments Inc purchased a new position in shares of uniQure in the third quarter worth about $53,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of uniQure in the third quarter worth about $69,000. Charles Schwab Investment Management Inc. increased its stake in shares of uniQure by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock worth $1,367,000 after purchasing an additional 16,464 shares in the last quarter. FMR LLC increased its stake in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Finally, PEAK6 Investments LLC purchased a new position in shares of uniQure in the third quarter worth about $260,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.